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Determination of endocannabinoid receptor antagonist SR141716
(rimonabant) in plasma by liquid chromatograph
tandem mass spectrometry
Melissa McCulloch , Xiang Zhou , Yan Xu , Steve Brunell , Linda Spear
Introduction
SR141716 [5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-
methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide] (Fig. 1)
also known as rimonabant is an endocannabinoid receptor
antagonist developed by Sanofi-Aventis [1]. The drug is
believed to interact with the G-protein coupled CB1 receptor in
the brain [2]. It has been reported that the binding of endocan-
nabinoid to CB1 receptor on the presynaptic neuron produces
several biochemical consequences, including inhibition of
Ca2+ channels [3]; activation of K+ channels [4]; inhibition of
adenylate cyclase (AC) [5]; and activation of mitogen-activated
protein kinase (MAPK) [6]. The effect of endocannabinoids on
the Ca2+ and K+ ion channels results in a reduction of neuronal
excitability and a suppression of neurotransmitter release.
Additionally, binding to CB1 receptor results in blocking AC,
which disrupts the conversion of ATP to cAMP, combined
with the activation of MAPK, has an overall effect on gene
expression [7].
The administration of SR141716 to rodents has shown to
reduce the rewarding/reinforcing behaviors of several drugs of
abuse including heroin [8], cocaine [9], nicotine [10] and alco-
hol [11]. Studies suggest that SR141716 may be successful in
the treatment of addiction because it affects dopamine neuronal
activity, thereby regulating the reward strength circuitry [10].
Further, there is evidence that rodents administered this drug
show a marked decrease in food consumption, suggesting it as
a potential treatment for obesity [12]. Studies show that by blo-
cking endocannabinoids from binding to the CB1 receptor, there
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Fig. 1. The chemical structures of SR141716 and AM251.
is an effect on appetite, food consumption and energy balance
[13].
SR141716 is the subject of heavy clinical investigation. Cur-
rently, SR141716 is in a phase II clinical trial for the treatment of
alcoholism [14] and a phase III clinical trial for the treatment of
diabetes [15]. A European clinical trial investigating SR141716
for the treatment of obesity has been completed [16]. Despite the
recent withdrawal of a new drug application in the United States
by Sanofi-Aventis, SR141716 has been approved to treat obesity
and overweight patients that have associated cardiovascular risk
in 42 countries, under the brand name Acomplia®.
The studies of SR141716 pharmacology and toxicology
necessitate an analytical method for the measurement of this
drug in biological fluids. A recent SciFinder Scholar search
revealed only one paper that described the use of fused-core
silica column with HPLC-APCI-MS/MS for the determina-
tion of rimonabant in mouse plasma [19]. However, this paper
focused on the comparison of chromatographic performances
between fast HPLC technology and ultrahigh-pressure liquid
chromatography rather than the analytical method validation. To
date, there is no validated analytical method publicly available
for quantitative measurement of SR141716. This work describes
the development and validation of a liquid chromatograph tan-
dem mass spectrometric method for the direct quantitation of
SR141716 in both human and rat plasma. The internal standard
chosen for this method was AM251. A protein precipitation
protocol was developed for plasma sample preparation. The
drug and internal standard were separated on a C4 column and
detected by positive-electrospray-ionization tandem mass spec-
trometry (ESI+-MS/MS). The method developed has been used
to analyze SR141716 in rat plasma samples from an animal
study.
Experimental
Chemicals and solutions
Acetic acid, HPLC-grade acetonitrile, dimethyl sul-
foxide (DMSO), formic acid, and 1-(2,4-dichlorophenyl)
-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-
carboxamide trifluoroacetate salt (AM251, the internal
standard for this study), Cremophor EL, and Tween
80 were from Sigma–Aldrich (St. Louis, MO, USA).
5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-
piperidinyl-1H-pyrazole-3-carboxamide (SR141716) was
obtained from the National Institute of Mental Health
(Bethesda, MD, USA) Drug Repository with a NIMH code
S-705. Pooled human plasma was from Haemtech, Inc. (Essex
Junction, Vermont, USA) and donated by Dr. Michael Kalafatis
at Cleveland State University. Pooled rat plasma was prepared
with the untreated Sprague–Dawley rats using the procedure
described in Section 2.5.
A stock solution (1.00 mg/ml) of SR141716
(C22H21Cl3N4O) was prepared by weighing 1.12 mg of
the compound into a 1.5 ml Eppendorf tube (Eppendorf,
Westbury, NY, USA) and dissolving it with 1.12 ml of DMSO.
A stock solution (1.00 mg/ml) of AM251 trifluoroacetate
salt (C22H21N4OCl2I·C2HF3O2) was prepared by weighing
1.24 mg of the compound into a 1.5 ml Eppendorf tube and
dissolving it with 1.24 ml of DMSO. After the compounds
had dissolved in DMSO, both SR141716 and AM251 stock
solutions were transferred to 1.5 ml amber glass autosampler
vials, sealed with parafilm, and were stored at −20 ◦C when
not in use.
A working solution (100g/ml) of SR141716 was prepared
by a dilution (1/10) of the SR141716 stock solution with DMSO.
A working solution (2.00g/ml) of AM251 was prepared by
a three-step dilution (1/8.3, 1/10, 1/5) of the AM251 trifluo-
roacetate salt stock solution with DMSO. A mobile phase for
liquid chromatographic separation was prepared by mixing 0.1%
HCOOH and 99.9% CH3CN/H2O (50:50, v/v). All solutions
were stored at 4 ◦C when not in use.
Preparation of plasma calibrators and controls
Pooled human and Sprague–Dawley rat plasmas containing
no detectable SR141716 were used as the blank plasmas to pre-
pare human and rat plasma calibrators and controls for this study.
SR141716 standard solutions (0.0100, 0.0200, 0.100, 0.150,
0.200, 1.00, 1.50, 2.00, 10.0, 15.0 and 20.0g/ml) were pre-
pared by a serial dilution of the working solution (100g/ml)
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with DMSO. SR141716 plasma calibrators (0.500, 1.00, 5.00,
10.0, 50.0, 100, 500 and 1.00 × 103 ng/ml) were prepared by a
1:20 dilution of the corresponding SR141716 standard solutions
with the blank plasma. SR141716 plasma controls (7.50, 75.0
and 750 ng/ml) were prepared by a 1:20 dilution of the corres-
ponding SR141716 standard solutions with the blank plasma.
All plasma samples were stored at −20 ◦C when not in use.
Sample preparation by protein precipitation
Plasma SR141716 calibrators, QCs and animal samples were
prepared by protein precipitation using the following proto-
col. First, 200l of plasma sample was pipetted into a 1.5 ml
Eppendorf tube followed by 10.0l of the AM251 working
solution (2.00g/ml) and 50.0l of acetic acid. After vortex
mixing, 1.00 ml of acetonitrile was added. The solution was
then mixed again by vortexing and centrifuged for 15 min at
13,000 × g. After centrifugation, the supernatant was transfer-
red to a 1.5 ml Eppendorf tube, and evaporated to dryness in a
DNA 120 SpeedVac® (ThermoSavant, Hollbrook, NY, USA) at
65 ◦C for 90 min. Prior to analysis, the sample was reconstituted
in 200l of the mobile phase.
. Recovery study
The recovery of SR141716 by the protein precipitation pro-
cedure was accessed using SR141716 plasma controls and
SR141716 reference solutions at three different concentrations
(7.50, 75.0 and 750 ng/ml). The reference solutions contained
the same matrix as that of plasma controls, which were prepared
using blank plasma as samples by the same procedure as that
of plasma controls, and reconstituted in the mobile phase with
corresponding SR141716 concentrations.
Animal study
Male offspring of Sprague–Dawley rats (Taconic Farms) bred
in Binghamton University’s vivarium were used in this expe-
riment. On postnatal (P) day 1, litters were culled to 7–10
subjects, with six males and four females retained whenever
possible. Animals were weaned on P21, housed in same-sex
pairs and maintained on a 14/10 h light/dark cycle (lights
on at 7 a.m.) with food and water available ad libitum. All
experimental procedures were approved by the Institutional
Animal Care and Use Committee at Binghamton Univer-
sity.
The average age of the animals was 70 days. The average
body weight of the animals was 300 g. SR141716 was delive-
red as a suspension of 2.0% Cremaphor EL, 0.1% Tween 80
and deionized water. All injections were given intraperitoneally
(i.p.) 10 mg/kg in a volume of 5 ml. The animals were decapi-
tated at 30 min and 12 h. Trunk blood samples were obtained
by allowing the blood to drain into centrifuge tubes. An ave-
rage of 3 ml of blood was collected in tubes containing 0.1 ml
of 0.1 M EDTA. High-speed centrifugation was used to separate
the plasma from whole blood. Plasma was stored at −80 ◦C until
analysis.
Instrumentation
The instrumentation system used in this work consisted
of an HP1100 pump by Hewlett Packard (Palo Alto, CA,
USA), an HP1100 autosampler, a stainless steel in-line filter
(0.5m pore, 0.23l dead volume) by Upchurch Scienti-
fic (Oak Harbor, WA, USA), a YMCTM Pro C4 cartridge
column (3m, 120 A˚, 2.0 mm × 50 mm) by Waters (Milford,
MA, USA), a stainless steel splitting tee (1/16 in. × 0.25 mm)
by Valco (Houston, TX, USA), and a Quattro II triple quadru-
pole mass spectrometer by Micromass (Manchester, UK). The
fluidic connection of the system was made using high-pressure
polyether ether ketone (PEEK) tubing (0.0625 in. o.d., 0.0100 in.
i.d.). The post-column split ratio was 1:2 with a smaller flow
(ca. 63l/min) to the MS detector and the larger one to the
waste.
Liquid chromatographic separation
Analytical separation was performed on a Waters YMCTM
Pro C4 cartridge column. Prior to the analysis, the cartridge
column was first equilibrated with the mobile phase at a flow rate
of 0.200 ml/min for about 15 min. During the analyses, 20l of
sample was injected by the autosampler and carried onto the car-
tridge column by the mobile phase at a flow rate of 0.200 ml/min.
SR141716 and AM251 (internal standard) were separated from
the matrix and retained on the column with retention times of 6.8
and 7.8 min, respectively. The total run time was about 10.0 min
per sample.
Mass spectrometric detection
The Micromass Quattro II triple quadrupole mass spectro-
meter was operated under the positive electrospray ionization
mode (ESI+). The mass spectrometer was tuned by infusion of a
mixture of SR141716 (1.0g/ml) and AM251 (1.0g/ml) in the
mobile phase at a flow rate of 3l/min with a syringe pump (Har-
vard Apparatus, South Natick, MA, USA). Ionization conditions
were optimized as follows: nitrogen sheath and desolvation gas
at 10 and 350 l/h, capillary at 3.5 kV, HV lens at 0.5 kV, cone at
40 V, skimmer at 1.5 V, RF lens at 0.2 V, ion source temperature
at 95 ◦C, ion energy at 1.0 V, low- and high-mass resolution at
15, and multiplier at 700 V. Full-scan spectra were acquired in
the continuum mode at a scan rate 400 u/s.
Multiple-reaction-monitoring (MRM) mode was used for
quantitation, which was set as follows: m/z 463 → 363 for
SR141716, m/z 555 → 455 for AM251, argon collision gas at
2.0–2.5bar, cone at 40 V, collision energy at 20 V for both
analytes, low- and high-mass resolution at 10 for quadrupole 1
and 15 for quadrupole 3, dwell time at 0.1 s, and the inter-scan
delay at 0.01 s. The ionization parameters were the same as those
described previously.
Data analysis
Data acquisition and peak integration were accomplished
using the Micromass Masslynx software (version 3.4). The
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peak-area ratios of SR141716 plasma calibrators to the internal
standard were plotted against plasma SR141716 concentra-
tions for a regression equation. SR141716 concentration of
an unknown plasma sample was determined by the regression
equation after obtaining the peak-area ratio of SR141716 in
the unknown to the internal standard from the mass chroma-
togram.
Results and discussion
Solvent selection
SR141716 and AM251 (Fig. 1) are carboxamide deriva-
tives, which have low solubilities in water. It is not possible to
directly dissolve either compound in plasma. Protonation of the
Fig. 2. The mass spectra of SR141716 and AM251, and their major fragments. The experimental conditions were the same as those described in Section 2.8.
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SR141716 and AM251 with 0.1 M HCl has little effect on dis-
solving the compounds in aqueous solution. Although CH3OH
could dissolve the compounds, it was not feasible to use in pre-
paration of plasma calibrators and controls because it causes
protein precipitation. As previously reported, as little as 1% of
methanol could cause protein precipitation and resulted in poor
reproducibility in analytical measurement [17]. Therefore, a sui-
table solvent that does not precipitate plasma protein was sought
for SR141716 and AM251 standard solutions.
Our experiments showed that DMSO could dissolve both
SR141716 and AM251 easily within the concentration range
used in this work, and the addition of DMSO up to 25% did not
cause protein precipitation from plasma. Furthermore, the use
of DMSO did not compromise the detection sensitivity of the
analytes by mass spectrometer. Hence, DMSO was chosen as
the solvent for SR141716 and AM251 stock and standard solu-
tions. In this work, the percent composition of DMSO in plasma
calibrators and controls was limited to 10% (v/v) to assure that
no protein precipitation occurred.
Plasma sample preparation
The feasibility of on-line solid-phase extraction (e.g., Waters
Oasis HLB cartridge column) was initially tested for plasma
sample preparation. However, due to the hydrophobicity of the
analytes, there was significant carryover between analyses.
To avoid the considerable error by carryover, a protein pre-
cipitation protocol was developed that used CH3CN (100%) as
deproteinizing solvent. Prior to the protein precipitation, ace-
tic acid was added to plasma samples to reduce the interaction
between the analytes and the plasma proteins. The use of acetic
acid did not only improve the extraction efficiency but also pro-
mote the protonation of SR141716 and AM251 for improved
sensitivity of ESI+-MS–MS detection. Our study also showed
that reduced CH3CN percentage (e.g., 70%) resulted in incon-
sistent recovery across the concentration range being studied.
This might be due to the change in partition isotherm at lower
CH3CN content.
Liquid chromatographic separation
Several analytical columns and mobile phase compositions
were tested for this method. Firstly, using a Waters YMCTM
Pro C18 cartridge column (3m, 120 A˚, 2.0 mm × 50 mm)
and a mobile phase of 90% CH3OH/0.1% HCOOH in water,
co-elution of SR141716 and the internal standard AM251 at
retention times of 2.5 and 2.8 min was observed. Secondly,
using a mobile phase of 70% CH3CN/0.1% HCOOH in water,
a baseline separation of SR141716 and the internal standard
was achieved at 4.6 and 5.6 min on the Waters YMCTM Pro
C18 cartridge column. Thirdly, to reduce the consumption of
organic solvent, a Waters YMCTM Pro C8 cartridge column
(3m, 120 A˚, 2.0 mm × 50 mm) was tested. Using a mobile
phase composition of 50% CH3CN/0.1% HCOOH in water, a
partial separation of SR141716 and the internal standard was
observed at 13.5 and 17.0 min. Finally, to optimize the separa-
tion time, a Waters YMCTM Pro C4 cartridge column (3m,
120 A˚, 2.0 mm × 50 mm) and a mobile phase composition of
50% CH3CN/0.1% HCOOH in water were used, which gave a
baseline separation of SR141716 and the internal standard with
Fig. 3. The proposed major fragmentation of SR141716 and AM251.
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retention times of 6.8 and 7.8 min. Therefore, a Waters YMCTM
Pro C4 cartridge column and a mobile phase composition of 50%
CH3CN/0.1% HCOOH in water were adopted for the subsequent
analytical separations.
Mass spectrometric detection
Due to their chemical structures, SR141716 and AM251 are
more easily protonated then deprotonated in electrospray ioniza-
tion; therefore, positive electrospray ionization mode was used
for analyte identification and quantitation. The full-scan spectra
(Fig. 2A and B) showed that SR141716 produced a predominant
protonated molecular ion at m/z 463 and AM251 at m/z 555. The-
refore, these ions were chosen as parent ions for fragmentation
in the multiple-reaction-monitoring (MRM) mode. The daughter
spectra of the parent ions revealed that the predominant daughter
fragments were m/z 363 for SR141716 and m/z 455 for AM251
(Fig. 2C and D). The predominant product ions were 100 amu
less than their parent ions. By comparing the chemical structures
of SR141716 and AM251, the fragmentation reactions could be
proposed (Fig. 3). These product ions were chosen for analyte
quantitation. The specificity of the MRM mode for SR141716
and AM251 was illustrated by the mass chromatograms (Fig. 4),
which showed no interference from the plasma matrices.
Recovery
The recovery studies were conducted using SR141716
plasma controls and SR141716 reference solutions at three dif-
ferent concentrations (7.50, 75.0 and 750 ng/ml). The absolute
recoveries of SR141716 and the internal standard were deter-
mined by comparing the mean peak areas of SR141716 and
internal standard in the plasma controls to those of SR141716
and the internal standard in the reference solutions. The rela-
tive recoveries of SR141716 were determined by comparing the
mean-peak-area ratios of SR141716 to the internal standard in
the plasma controls to those of SR141716 to the internal standard
in the reference solutions.
As shown in Table 1, by triplicate measurements, the mean
absolute recoveries of SR141716 and the internal standard in
human plasma ranged 83.0–85.1% and 85.1–91.0%, respec-
tively. The mean relative recoveries of SR141716 in human
plasma ranged 92.0–99.2%. The improved relative recoveries
were attributed to the use of internal standard. Since there was
no significant difference observed between data from human and
Table 1
Absolute and relative recoveries of SR141716 and AM251 in human plasma
Compound 7.50 ng/ml 75.0 ng/ml 750 ng/ml
Recovery %CV Recovery %CV Recovery %CV
SR141716 83.0 2 83.7 4 85.1 5
AM251 87.3 3 91.0 4 85.8 4
SR141716/AM251 95.2 3 92.0 0.6 99.2 1
The number of measurements was 3 for each datum point. The concentration of
the internal standard AM251 was 100 ng/ml.
Fig. 4. The representative mass chromatograms of human plasma samples: (A)
the pooled human blank plasma; (B) the pooled human plasma spiked with
100 ng/ml AM251; and (C) the pooled human plasma spiked with 100 ng/ml
SR141716 and 100 ng/ml AM251.
rat plasma, rat plasma validation data were not shown.
Precision and accuracy
Intra- and inter-assay precision and precision of the method
were determined by analyzing SR141716 plasma controls at
three different concentrations (7.50, 75.0 and 750 ng/ml). Intra-
assay precision was determined by triplicate measurements of
the peak-area ratio of SR141716 to the internal standard from
a single sample at each concentration. Inter-assay precision
was determined by the triplicate measurements of the peak-area
ratio of SR141716 to the internal standard from three separate
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Table 2
Intra- and inter-assay precision of SR141716 in human plasma
[SR141716]
(ng/ml)
%CV (peak area of SR141716 to peak area of AM251)
Intra-run Inter-run
7.50 0.9 6
75.0 1 0.5
750 0.4 2
The concentration of the internal standard AM251 was 100 ng/ml. The number
of measurements was 3 for each datum point.
samples at the each concentration. As shown in Table 2, the
intra- and inter-assay precision expressed in terms of percent
coefficient of variation (%CV) ranged 0.5–1% and 0.5–6%,
respectively. Accuracy defined as the measured value to the
accepted value multiplies by 100%, were 105, 99.5 and 100%
at the concentrations of 7.50, 75.0 and 750 ng/ml by triplicate
measurements.
Linearity
The linear response determined by the peak-area ratios
of SR141716 to the internal standard versus the concentra-
tions of SR141716 was achieved over a concentration range
of 5.00–1000 ng/ml with a correlation coefficient of 0.999. A
mean calibration equation, y = 0.0196x, was derived from three
separate calibration curves over a 6-month period.
Detection limits
The limit of detection (LOD) and the lower limit of quantita-
tion (LLOQ) for the method were calculated as 3 and 10 times
of signal-to-noise ratio (peak-to-peak). Based on five replicate
measurements of 5.00 ng/ml SR141716 plasma calibrator, the
LOD and LLOQ of the method were calculated to be 1.09 and
3.62 ng/ml, respectively.
Stability
The stability of SR141716 in plasma was determined by three
aliquots at each low and high controls after three freeze (−20 ◦C)
and thaw (room temperature) cycles. The results showed no
significant degradation with relative errors −8.9 and 8.6% for
the low and high controls. The short-term temperature stability
was assessed by keeping the controls at room temperature for
4, 8 and 24 h. Under the test conditions, the maximum relative
error observed was 6.6% which showed no significant loss of
SR141716. The SR141716 stock solution and plasma samples
were respectively kept at −20 and −80 ◦C, which were stable
for at least 6 months.
Analysis of SR141716 in rat plasma samples
The validated method was used to analyze SR141716 in
plasma samples from rats after intraperitoneal injection of
SR141716 at the dose of 10 mg/kg. In the analyses, the frozen rat
plasma samples and blank plasma were thawed to room tempe-
Fig. 5. The representative mass chromatograms of rat plasma samples: (A)
the untreated rat plasma; (B) the rat plasma collected 30 min after injection
of 10 mg SR141716/kg rat; (C) the rat plasma collected 12 h after injection of
10 mg SR141716/kg rat; and (D) the untreated rat plasma spiked with 5.00 ng/ml
SR141716.
rature, 200l of plasma samples together with the blank plasma
were prepared by the protein precipitation procedure described
in Section 2.3 and analyzed by the LC-MS–MS method. The
resultant mass chromatograms are shown in Fig. 5. While there
was no interference found in the untreated rat plasma (Fig. 5A),
SR141716 was detected in rat plasma at 30 min and 12 h injec-
tion of SR141716 (Fig. 5B and C). By comparing with Fig. 5D,
the plasma SR141716 concentrations at these time points were
either lower or higher than 5 ng/ml. Furthermore, the plasma
concentration at 12 h after injection was higher than that at
30 min. This finding was consistent with the pharmacokinetic
data in the US FDA briefing document (NDA 21-888, June 13,
2007), which showed a mean half-life of ca. 16 days for the drug
in human [18]. Although the dose and the sampling times in this
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preliminary study were not optimized for the pharmacokine-
tic study, the results have demonstrated the applicability of the
method for the measurement of SR141716 in plasma samples.
Conclusions
A rapid and specific liquid chromatograph tandem mass spec-
trometric method has been developed and validated for the
quantitative measurement of SR141716 in both human and rat
plasma matrices. Plasma SR141716 can be prepared by pro-
tein precipitation, separated by C4 column, and quantified by
ESI+-MS–MS. The fragmentation reactions of SR141716 and
the internal standard AM251 have been proposed. This method
has high sample recovery, wide linear calibration range, and low
limit of quantitation. It has been used to analyze SR141716 in
plasma from rats that received intraperitoneal injections of the
drug. Thus, it may be useful for pharmacological and toxicolo-
gical studies of this drug.
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